Maravai LifeSciences
MRVI
144 hedge funds and large institutions have $3.51B invested in Maravai LifeSciences in 2021 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 41 increasing their positions, 34 reducing their positions, and 30 closing their positions.
87% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 30
28% more capital invested
Capital invested by funds: $2.73B → $3.51B (+$773M)
22% more funds holding
Funds holding: 118 → 144 (+26)
21% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 34
0.97% more ownership
Funds ownership: 100.83% → 101.8% (+0.97%)
31% less call options, than puts
Call options by funds: $2.29M | Put options by funds: $3.34M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$132M |
| 2 |
Select Equity Group
New York
|
+$132M |
| 3 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$56.6M |
| 4 |
Morgan Stanley
New York
|
+$45.8M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
D1 Capital Partners
New York
|
-$166M |
| 2 |
Holocene Advisors
New York
|
-$39.8M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$31M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28.3M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$27.4M |
MRVI Hedge Fund Activity: Q1 2021 in Review
144 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2021, worth a combined $3.51B — up 28% from $2.73B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new MRVI positions and 30 closed out — a net gain of 26 holders — while 41 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $132M. The largest seller was D1 Capital Partners, exiting entirely with an estimated $166M sold.
- 144 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2021, up from 118 in Q4 2020.
- Funds reported $3.51B of Maravai LifeSciences stock for Q1 2021, up 28% quarter-over-quarter.
- 56 funds opened new Maravai LifeSciences positions in Q1 2021 and 30 closed out, a net change of +26 holders.
- The largest Maravai LifeSciences buyer in Q1 2021 was Fidelity Investments, an estimated $132M added.
- The largest Maravai LifeSciences seller in Q1 2021 was D1 Capital Partners, an estimated $166M sold.
Based on aggregated 13F filings for Q1 2021.